In the ongoing denosumab biosimilar race, Sandoz has reached one of the milestones with its Jubbonti version, as the biosimilar to Amgen’s Prolia was recently approved by Health Canada.
Jubbonti, a human monoclonal antibody and RANK ligand inhibitor, should be available for Canadians in the coming months as a 60mg/mL solution in a single-use prefilled